In recent analyst activity, Needham has made adjustments to its price target for Axsome Therapeutics (AXSM, Financial). Analyst Ami Fadia has maintained a "Buy" rating on the stock, indicating continued confidence in the company's prospects despite a slight adjustment in the price target.
The price target has been lowered from $153.00 to $150.00, reflecting a change of approximately -1.96%. This adjustment in the price target may suggest a reassessment of Axsome Therapeutics' (AXSM, Financial) short-term performance potential while still holding a bullish stance on its long-term value.
This update was released on June 9, 2025, and it reinforces the analyst's previously positive outlook on Axsome Therapeutics (AXSM, Financial), as the "Buy" rating remains unchanged. Investors may want to consider this information when evaluating their potential investment strategies for Axsome Therapeutics.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 17 analysts, the average target price for Axsome Therapeutics Inc (AXSM, Financial) is $176.53 with a high estimate of $210.00 and a low estimate of $146.00. The average target implies an upside of 57.74% from the current price of $111.91. More detailed estimate data can be found on the Axsome Therapeutics Inc (AXSM) Forecast page.
Based on the consensus recommendation from 18 brokerage firms, Axsome Therapeutics Inc's (AXSM, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Axsome Therapeutics Inc (AXSM, Financial) in one year is $259.61, suggesting a upside of 131.98% from the current price of $111.91. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Axsome Therapeutics Inc (AXSM) Summary page.
